Italia markets closed

FTSE MIB
34.249,77
+310,02(+0,91%)
Dow Jones
38.239,66
+153,86(+0,40%)
Nasdaq
15.927,90
+316,14(+2,03%)
Nikkei 225
37.934,76
+306,28(+0,81%)
Petrolio
83,66
+0,09(+0,11%)
Bitcoin EUR
59.681,20
+784,09(+1,33%)

Carmell Corporation (CTCX)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,0900

-0,0900

(-4,13%)

Alla chiusura: 04:00PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	40,222M
Beta (5 anni mensile)	0,31
Rapporto PE (ttm)	N/D
EPS (ttm)	-1,5300
Prossima data utili	N/D
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	N/D

Tutte

GlobeNewswire
Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics
PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative care company, today announced the completion of post-merger integration with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company (“Axolotl”). As part of the post-merger planning process, Carmell announced the following changes effective September 1, 2023: Rajiv Shukla, Executive Chairman of Carmell to serve as Chairman & CEO of Carmell.Randy Hubbell to step down